Purinergic receptor ligands in clinical studies for treating inflammatory diseases
| Drug | Target | Agonist or Antagonist | Disease | Status | Company | References |
|---|---|---|---|---|---|---|
| CE-224,535 | P2X7 | Antagonist | Rheumatoid arthritis | Phase 2 | Pfizer | NCT00628095 |
| GSK1482160 | P2X7 | Antagonist | Inflammatory pain (arthritis) | Phase 1 | Glaxo SmithKline | NCT00849134 |
| PBF-680 | A1 | Antagonist | Asthma | Phase 1 | Palabiofarma | NCT01845181 |
| PBF-680 | A1 | Antagonist | Asthma | Phase 2 | Palabiofarma | NCT02635945 |
| UK 432097 | A2A | Agonist | COPD | Phase 2 | Pfizer | NCT00430300 |
| Poclidenoson | A3 | Agonist | Rheumatoid arthritis | Phase 3 | CanFite Pharma | NCT02647762 |
| Poclidenoson | A3 | Agonist | Psoriasis | Phase 3 | CanFite Pharma | NCT00428974 |
| PBF-677 | A3 | Agonist | Ulcerative colitis | Phase 2 | Palabiofarma | NCT02639975 |